3-dimensional Pharmaceuticals, Inc.

Janssen Pharmaceutica Nv

Farah Ali

Jeremy Mark Travins

Kristi A Leonard

Shelley K Ballentine

Heather Rae Hufnagel

Ehab Khalil

Maxwell David Cummings

Nalin L Subasinghe

Mark James Wall

Sanath K Meegalla

Jinsheng Chen

Hui Huang

Michael Peter Winters

Wenxi Pan

Joan Gushue

Joan M Gushue

Roger Francis Bone

Kenneth J Wilson

M Jonathan Rudolph

Jonathan Rudolph

Kenneth T Wilson

Disclosed are compounds for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade. The compounds are of Formula I or a solvate, hydrate, pharmaceutically acceptable salt, or prodrug thereof; wherein R, R, and Rare as defined in the specification, as are A Z, Q, Rand R.

Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions

The present invention is directed to conjugated complement cascade inhibitors, and a method of treating a patient using a conjugated complement cascade inhibitor.

Conjugated complement cascade inhibitors

Disclosed are compounds for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade. The compounds are of Formula I or a solvate, hydrate, pharmaceutically acceptable salt, or prodrug thereof; wherein R, R, and Rare defined in the specification, as are A Z, Q, Rand R.

Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R, R, R, Rand Rare defined in the specification, Z is SO or SO, and Ar is an aromatic or heteroaromatic group as defined herein. 

Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions

Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R, R, R, Rand Rare defined in the specification, Z is SO or SO, and Ar is an aromatic or heteroaromatic group as defined herein.

Growing community of inventors

Exton, PA, United States of America

Farah Ali